RxDoctor Payments Data

Michael Festino, MD

Cardiovascular Disease · Saco, MENPI 1124010111

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 30.3% of the total. Reporting peaked in 2021 at $102 and has fallen 54.1% since, to $47 in 2023.

$263in general payments, 2019–2025

Across 17 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$80
  • GSK$45
  • Amgen$35
  • Bayer$30
  • Pfizer$28
  • Heartflow, Inc.$17
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$263100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)6$80
GSK3$45
Amgen2$35
Bayer1$30
Pfizer2$28
Heartflow, Inc.1$17
Eisai Inc.1$15
Amryt Pharma Holdings Ltd1$13

How this compares

$263 in reported general payments places this provider in the 55th percentile of 99 cardiovascular disease providers in Maine.

See all cardiovascular disease providers in Maine

Medicare billing

Part B allowed, 2024
$56,117
Medicare patients
86
Services billed
756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HetliozTasimelteon12$382,857
EliquisApixaban67$99,781
JardianceEmpagliflozin42$59,074
OzempicSemaglutide49$52,847
XareltoRivaroxaban18$13,561
Spironolactone-HctzSpironolact/Hydrochlorothiazid83$4,242
Ezetimibe200$3,173
Atorvastatin Calcium317$2,968
Omeprazole135$2,937
Fluticasone Propionate20$2,571
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,428
Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine13$1,798
Metformin Hcl ErMetformin Hcl96$1,644
Atenolol184$1,614
Rosuvastatin Calcium144$1,586

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$99,78167 claims
AbbVieSynthroid$80$62618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 99 cardiovascular disease providers in Maine.

Other cardiovascular disease in Saco

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →